Weiming Y. Li - Publications

Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.

Journal: Drug design, development and therapy

Published: March 26, 2026

Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis.

Journal: JCO oncology practice

Published: March 10, 2026

Analysis of serum herbicide levels of exposure and determinants in middle-aged and elderly population

Journal: Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

Published: February 01, 2026

Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy.

Journal: Therapeutic advances in hematology

Published: January 27, 2026

Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.

Journal: Scientific reports

Published: December 26, 2025

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: November 05, 2025

Low-dose dasatinib in second-line therapy or beyond for the treatment of chronic-phase chronic myeloid leukemia: a real-world cohort study.

Journal: Frontiers in pharmacology

Published: October 28, 2025

Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Journal: Blood cancer journal

Published: October 22, 2025

The combination of alternating reduced-dose blinatumomab and hyper-CVAD as consolidation therapy in patients with newly-diagnosed adult B-cell acute lymphoblastic leukemia.

Journal: Therapeutic advances in hematology

Published: October 17, 2025

Heavy metals and PAHs drive ecological and health risks in Chinese water level fluctuation zones.

Journal: Journal of hazardous materials

Published: October 12, 2025

Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.

Journal: BMC cancer

Published: October 09, 2025

Safety and Efficacy of Flumatinib in Patients with Chronic Phase Chronic Myeloid Leukemia: A Real-Life Cohort Observational Study.

Journal: Blood and lymphatic cancer : targets and therapy

Published: October 09, 2025